|
Age (years), Mean (SD)
|
52.8 (16.1)
|
|
Age: < 20
|
1.5%
|
|
Age: 20–24
|
2.7%
|
|
Age: 25–34
|
10.1%
|
|
Age: 35–44
|
17.9%
|
|
Age: 45–54
|
21.3%
|
|
Age: 55–64
|
19.0%
|
|
Age: 65–74
|
18.9%
|
|
Age: 75–84
|
6.6%
|
|
Age: 85+
|
2.1%
|
|
Gender: Female
|
73.0%
|
|
Insurance type: Medicare
|
41.2%
|
|
Charlson comorbidity index score, Mean (SD)
|
1.77 (2.55)
|
|
Follow-up time
|
|
Proportion of patients with at least x days of follow-up
|
|
≥ 365 days
|
100.0%
|
|
≥ 730 days
|
62.6%
|
|
≥ 1095 days
|
36.3%
|
|
Mean follow-up (days)
|
973
|
|
Std. deviation
|
441
|
|
Median follow-up (days)
|
879
|
|
Received a DMT any time during follow-up
|
35.0%
|
|
Time (days) from MS diagnosis to receiving DMT, Mean (SD)
|
169 (258)
|
